Marker Therapeutics, Inc. (NASDAQ:MRKR – Get Free Report) saw a large increase in short interest in the month of October. As of October 30th, there was short interest totaling 176,136 shares, an increase of 61.4% from the October 15th total of 109,110 shares. Approximately 1.1% of the shares of the company are short sold. Based on an average daily trading volume, of 255,474 shares, the short-interest ratio is currently 0.7 days.
Wall Street Analyst Weigh In
MRKR has been the subject of several recent research reports. Zacks Research upgraded Marker Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Thursday, October 15th. Weiss Ratings lowered shares of Marker Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday. Finally, HC Wainwright restated a “buy” rating on shares of Marker Therapeutics in a research report on Friday, August 21st. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $10.00.
Read Our Latest Analysis on MRKR
Marker Therapeutics Stock Performance
Shares of NASDAQ MRKR traded down $0.04 during trading hours on Monday, hitting $0.83. The company’s stock had a trading volume of 135,857 shares, compared to its average volume of 199,889. The stock has a market cap of $13.81 million, a price-to-earnings ratio of -2.02 and a beta of 1.65. The business has a 50-day simple moving average of $1.05 and a 200-day simple moving average of $1.32. Marker Therapeutics has a 12 month low of $0.82 and a 12 month high of $2.46.
Marker Therapeutics (NASDAQ:MRKR – Get Free Report) last issued its quarterly earnings data on Monday, November 16th. The company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.12) by $0.02. The company had revenue of $1.29 million during the quarter, compared to the consensus estimate of $2.12 million. On average, equities research analysts forecast that Marker Therapeutics will post -0.64 EPS for the current year.
Hedge Funds Weigh In On Marker Therapeutics
An institutional investor recently bought a new stake in Marker Therapeutics stock. Concurrent Investment Advisors LLC bought a new position in Marker Therapeutics, Inc. (NASDAQ:MRKR – Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 67,963 shares of the company’s stock, valued at approximately $100,000. Concurrent Investment Advisors LLC owned about 0.41% of Marker Therapeutics as of its most recent filing with the Securities & Exchange Commission. 22.39% of the stock is owned by institutional investors.
About Marker Therapeutics
Marker Therapeutics is a clinical-stage biotechnology company focused on developing T-cell therapies for cancer. Its platform aims to produce T cells that recognize multiple tumor-associated antigens, with the goal of helping them target cancer cells while reducing the risk that tumors evade treatment by losing a single antigen. The company’s pipeline includes multi-antigen-specific T-cell candidates for blood cancers. Its programs have included MT-601, studied for lymphoma, and MT-401, developed for acute myeloid leukemia and other hematologic malignancies.
See Also
- Five stocks we like better than Marker Therapeutics
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Marker Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marker Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
